Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].

证券代码：301277 证券简称：新天地 公告编号：2025-004 新天地药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 公司取得国家药品监督管理局下发的《化学原料药上市申请批准通知书》， 该原料药在CDE原辅包登记信息平台显示状态为"A"。 三、 对公司的影响及风险提示 本次公司取得的马来酸氯苯那敏原料药《化学原料药上市申请批准通知书》 表明该原料药符合中国相关药品审评技术标准，已批准在国内上市制剂中使用， 将进一步丰富公司产品种类。 受市场环境等因素影响，上述原料药品种的具体上市销售情况取决于内外 部环境变化等多种因素，存在一定的不确定性。公司将按照相关法律法规的要 求对后续进展情况履行信息披露义务。敬请广大投资者理性投资，注意投资风 险。 2025年02月24日，新天地药业股份有限公司(以下简称"公司")收到国家 药品监督管理局核准签发的马来酸氯苯那敏原料药《化学原料药上市申请批准 通知书》，现将相关情况公告如下： | 化学原料药名称 | 通用名称：马来酸氯苯那敏 英文名/拉丁名：Chlo ...